Start-Up Quarterly Statistics, Q3 2010

Biopharma, medical device, and in vitro diagnostics start-ups brought in a total of $780 million in Q3 2010, a 29% jump from the previous quarter and a 50% increase from Q3 2009. A total of eight start-up acquisitions closed in Q3, quite a jump from the first two quarters of 2010. The third quarter saw 14 biopharma alliances covering a wide range of therapeutic categories, the most popular indication being cancer.

In the third quarter of 2010, biopharma, medical device, and in vitro diagnostics start-ups brought in a total of $780 million, a 29% jump from the previous quarter and a 50% increase from the third quarter of 2009. ( See Exhibit 1.) Biopharma companies did well in Q3, bringing in $446 million, or 30% more than the previous quarter. Not so for in vitro diagnostics start-ups, which raised just $99 million, 39% less than they did in Q2. Device companies were the most successful at generating more funds compared with Q2 – with a 130% hike. (This spike was mostly due to Devicor Medical Products Inc.'s equity financing, which accounted for 66% of Q3's device total.)

Devicor was the clear fundraising champion in Q3. In what appears to be its first outside financing round (GTCR Golder...

More from Archive

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.